Momat Rhino Advance, spray 140 mcg+50 mcg/dose 75 doses

Azelastine, Mometazone

Indications

Seasonal allergic rhinitis in adults (from 18 years of age).

Pharmacological effect

Pharmacotherapeutic group: Preparations for the treatment of nasal diseases; decongestants and other drugs for topical use; corticosteroids

Pharmacological action

Combined drug with antiallergic and anti-inflammatory effects for topical use.

Azelastine is a histamine H1 receptor blocker, a phthalazinone derivative. It has antihistamine, antiallergic and membrane-stabilizing effects, reduces capillary permeability and exudation, inhibits the release of inflammatory mediators from mast cells (histamine, serotonin, leukotrienes, platelet-activating factor, etc.), causing bronchospasm and contributing to the development of early and late stages of allergic reactions and inflammation.

Mometasone is a synthetic corticosteroid for topical use. It has anti-inflammatory and antiallergic effects when used in doses at which systemic effects do not occur. Inhibits the release of inflammatory mediators. Increases the production of lipomodulin, which is an inhibitor of phospholipase A, which causes a decrease in the release of arachidonic acid and, accordingly, inhibition of the synthesis of arachidonic acid metabolic products – cyclic endoperoxides, prostaglandins. Prevents the marginal accumulation of neutrophils, which reduces inflammatory exudate and the production of lymphokines, inhibits the migration of macrophages, and leads to a decrease in the processes of infiltration and granulation. Reduces inflammation by reducing the formation of a chemotaxis substance (impact on late allergy reactions), inhibits the development of an immediate allergic reaction (due to inhibition of the production of arachidonic acid metabolites and a decrease in the release of inflammatory mediators from mast cells).

Active ingredient

Azelastine, Mometasone

Composition

Active substances
azelastine hydrochloride 140 mcg
mometasone furoate 50 mcg
Excipients: Avicel RC-591 [microcrystalline cellulose, sodium carmellose] – 0.91 mg, sodium carmellose – 0.021 mg, dextrose – 3.5 mg, polysorbate 80 – 0.0175 mg, benzalkonium chloride – 0.014 mg, disodium edetate – 0.035 mg, neotame – 0.0007 mg, citric acid monohydrate – 0.0105 mg, sodium citrate – 0.021 mg, purified water – up to 70 mg.

Pregnancy

There have been no adequate and well-controlled studies of the drug in pregnant women.

In experimental studies, azelastine hydrochloride had a toxic effect on the fetus in mice, rats and rabbits.

The use of the drug during pregnancy and breastfeeding is contraindicated.

Contraindications

Recent surgery or trauma to the nose with damage to the mucous membrane of the nasal cavity – before the wound heals (due to the inhibitory effect of GCS on the healing process); children and adolescents under 18 years of age (due to the lack of relevant data); hypersensitivity to azelastine and mometasone.

With caution: respiratory tuberculosis (active and latent); untreated fungal, bacterial, systemic viral infection or infection caused by Herpes simplex with eye damage (as an exception, the drug can be used for these infections as prescribed by a doctor); untreated infection involving the nasal mucosa.

Side Effects

From the nervous system: headache, dizziness.

From the respiratory system: nosebleeds, discomfort in the nasal cavity (burning sensation, itching), ulceration of the nasal mucosa, sneezing, pharyngitis, sinusitis, upper respiratory tract infections.

From the digestive system: dysgeusia, nausea.

From the skin and subcutaneous tissues: rash, itching, urticaria.

Allergic reactions: hypersensitivity, anaphylactoid reactions.

Other: irritation of the pharyngeal mucosa, fatigue, drowsiness, weakness.

With long-term use of GCS in high doses, systemic side effects may develop, incl. glaucoma and cataracts.

Interaction

Azelastine – with intranasal use of azelastine, no clinically significant interactions with other drugs were detected.

Mometasone furoate, a combination therapy with loratadine, was well tolerated by patients. No effect of the drug on the concentration of loratadine or its main metabolite in the blood plasma was noted.

Manufacturer

Glenmark Pharmaceuticals Ltd, India